New catheter aims to tame stubborn AFib
NCT ID NCT07321002
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new shape-adaptive catheter that uses pulsed field ablation to treat persistent atrial fibrillation (AFib), a type of irregular heartbeat. 35 adults with persistent AFib will receive the procedure under general anesthesia. Researchers will check for serious side effects within 7 days and see if the treatment successfully restores normal heart rhythm.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PFLotus catheter and DePolar mapping system
- What this could lead to
- If successful, this could provide a safer and more effective way to treat persistent atrial fibrillation using a single catheter system.
- What could go wrong
- This is a small, early-stage trial with only 35 participants. The procedure carries risks like bleeding, heart damage, or irregular heartbeat. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERSISTENT ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a cholesterol drug keep atrial fibrillation at bay after ablation?
- Which ablation method best tames persistent AF? a Head-to-Head trial aims to find out
- Extra ablation target may cut AF recurrence in persistent cases
- New heart ablation tech under scrutiny: can it tame dangerous rhythms?
- New 3D heart imaging could sharpen ablation precision
- More zaps, better rhythm? trial tests extra ablations for AFib